<DOC>
	<DOCNO>NCT00124241</DOCNO>
	<brief_summary>This extension study patient previously complete Idenix Study NV-02B-003 . This study conduct compare safety effectiveness treatment beyond 1 year telbivudine telbivudine combine lamivudine , drug currently approve treatment hepatitis B .</brief_summary>
	<brief_title>An Extension Study Telbivudine , Lamivudine Telbivudine Plus Lamivudine Patients With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Patient complete protocol NV02B003 without serious adverse event attribute study drug Patient remain seropositive hepatitis B surface antigen ( HBsAg ) Other protocoldefined inclusion criterion may apply . Patient pregnant breastfeeding Patient sign decompensated chronic hepatitis B Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>